BLUE Brings Back Treatment From Marketing Suspension

The stock experienced a steep bear gap related to this suspension in February

Deputy Editor
Jul 9, 2021 at 10:36 AM
facebook X logo linkedin


The shares of bluebird bio Inc (NASDAQ:BLUE) are higher today, on news that the biotech company is lifting its voluntary marketing suspension of its gene therapy treatment, Zynteglo. The drug, which treats a rare blood condition, received a positive recommendation from a European regulator, which says its benefit-risk balance remains favorable. BLUE is up 1.5% to trade at $30.90 at last check. 

The stock has struggled to climb back up the charts after its steep mid-February bear gap, which occurred after the company placed its sickle cell disease treatment LentiGlobin on temporary suspension following a serious adverse reaction, and suspended Zynteglo as it is made with the same component. However, the stock appears to have found a floor at the $30 level, though long-term pressure at the 120-day moving average still looms. Year-to-date, the equity is down 28.6%. 

Analysts are mostly hesitant toward BLUE, with 11 of the 14 in coverage carrying a "hold" rating, with three at a "strong buy." Meanwhile, short interest makes up 8.1% of the stock's available float, or over four days' worth of pent-up buying power. 

The options pits, on the other hand, have been overwhelmingly bullish. This is per bluebird stock's 50-day call/put volume ratio of 22.67 at the International Securities Exchange (ISE), Cboe Options Exchange (CBOE), and NASDAQ OMX PHLX (PHLX), which stands higher than 92% of readings from the past year. 

It's also worth pointing out that BLUE ranks low on the Schaeffer's Volatility Scorecard (SVS), with a score of just 9 out of 100. In other words, the security has consistently realized lower volatility than its options have priced in, making the stock a potential premium-selling candidate.

 

 

Target Effortless Triple-Digit Gains Every Sunday Evening For Life!

This is your chance to triple your profit potential on Sunday evenings, without spending all your free time watching the market.

On Sundays, as a Weekend Plus subscriber, you’ll get up to 6 trades every Sunday, each targeting gains of 200% or more.

Start targeting gains like the ones our subscribers have seen recently, including:

213.3% GAIN on AutoNation calls
100.0% GAIN on Monster Beverage calls
100.4% GAIN on Walgreens Boots Alliance puts
100.4% GAIN on ON Semiconductor calls
257.7% GAIN on Dell calls

101.0% GAIN on Apollo Global Management calls
103.6% GAIN on JP Morgan  Chase calls
105.3% GAIN on DraftKings calls
101.3% GAIN on Airbnb calls
203.0% GAIN on Shopify calls
102.0% GAIN on Cboe Global Markets calls
100.9% GAIN on Boeing calls
102.1% GAIN on Microsoft puts
102.3% GAIN on First Solar calls
101.5% GAIN on PulteGroup calls
101.0% GAIN on Apple calls
209.4% GAIN on NXP Semiconductors calls
100.8% GAIN on Uber Technologies calls
100.4% GAIN on Academy Sports and Outdoors puts
102.2% GAIN on Trade Desk calls
100.8% GAIN on DoorDash calls
100.0% GAIN on Camping World Holdings puts
100.0% GAIN on Cboe Global Markets calls
100.2% GAIN on C3.ai calls
238.5% GAIN on Oracle calls

 
 
 


 
 

Rainmaker Ads CGI